Table 3.
Distribution of demographics and comorbidities over time for patients receiving PPM
| Overall comparisons between groups | |||||||
|---|---|---|---|---|---|---|---|
| 1988 – 1993 (N=214) |
1994 – 1999 (N=318) |
2000 – 2005 (N=449) |
2006 – 2011 (N=401) |
2012 – 2018 (N=545) |
Total (N=1927) |
p value⁑ | |
| Age | 0.04 | ||||||
| Mean (SD) | 75.4 (13.5) | 75.4 (13.7) | 76.8 (11.8) | 76.8 (12.7) | 77.9 (11.7) | 76.7 (12.5) | |
| Range | (23.0–97.0) | (26.0–100.0) | (25.0–99.0) | (21.0–100.0) | (23.0–99.0) | (21.0–100.0) | |
| Sex | 0.005 | ||||||
| Female | 108 (50.5%) | 150 (47.2%) | 246 (54.8%) | 182 (45.4%) | 236 (43.3%) | 922 (47.8%) | |
| Male | 106 (49.5%) | 168 (52.8%) | 203 (45.2%) | 219 (54.6%) | 309 (56.7%) | 1005 (52.2%) | |
| Atrial fibrillation | 139 (65.0%) | 208 (65.4%) | 333 (74.2%) | 288 (71.8%) | 407 (74.7%) | 1375 (71.4%) | 0.005 |
| Coronary artery disease | 160 (74.8%) | 255 (80.2%) | 349 (77.7%) | 305 (76.1%) | 366 (67.2%) | 1435 (74.5%) | 0.0001 |
| Congestive heart failure | 166 (77.6%) | 236 (74.2%) | 341 (75.9%) | 263 (65.6%) | 340 (62.4%) | 1346 (69.8%) | <0.0001 |
| Chronic kidney disease | 77 (36.0%) | 160 (50.3%) | 254 (56.6%) | 202 (50.4%) | 263 (48.3%) | 956 (49.6%) | <0.0001 |
| Chronic obstructive pulmonary disease | 71 (33.2%) | 136 (42.8%) | 183 (40.8%) | 139 (34.7%) | 180 (33.0%) | 709 (36.8%) | 0.01 |
| Diabetes | 87 (40.7%) | 158 (49.7%) | 267 (59.5%) | 277 (69.1%) | 381 (69.9%) | 1170 (60.7%) | <0.0001 |
| Hypertension | 161 (75.2%) | 276 (86.8%) | 409 (91.1%) | 372 (92.8%) | 480 (88.1%) | 1698 (88.1%) | <0.0001 |
| Obesity | 106 (49.5%) | 162 (50.9%) | 224 (49.9%) | 233 (58.1%) | 317 (58.2%) | 1042 (54.1%) | 0.01 |
| Valvular heart disease | 39 (18.2%) | 43 (13.5%) | 76 (16.9%) | 68 (17.0%) | 90 (16.5%) | 316 (16.4%) | 0.62 |
| Hyperlipidemia | 79 (36.9%) | 193 (60.7%) | 346 (77.1%) | 350 (87.3%) | 471 (86.4%) | 1439 (74.7%) | <0.0001 |
| Any cancer* | 14 (6.5%) | 47 (14.8%) | 96 (21.4%) | 93 (23.2%) | 135 (24.8%) | 385 (20.0%) | <0.0001 |
| Charlson comorbidity index | |||||||
| Mean (SD) | 1.1 (1.3) | 1.6 (1.5) | 1.9 (1.6) | 2.0 (1.8) | 2.3 (1.9) | <0.001 | |
*
including lymphoma, leukemia and metastatic solid organ tumors
⁑
p-value compares demographics over time groups